Aberrant Tyrosine kinase (TK) activity is critical in many hematological disorders, including chronic myeloid leukemia (CML) characterized by the constitutive activity of BCR-ABL. ABL therefore represented a crucial target for new therapeutic strategies. The molecular pathways abnormally activated by the oncoprotein are summarized and they may represent additional opportunities to develop new drugs to overcome the resistance to TK inhibitors. Among them the PI3K/Akt pathway can be effectively blocked by mTOR inhibitors, or RAS pathway, resulting MEK1/2 and MAPK activation can be targeted. Furthermore, mitotic kinases can be blocked by Aurora kinase inhibitors or Pim kinases by selective serine-threonine kinase inhibitors. Finally, the abnormal pathways sustaining the self renewal of leukemic stem cells are described as possible targets to completely eradicate the leukemic clone including Hedgehog pathway which can be blocked by Smo inhibitors and CXCR4/SDF1 axis which can be targeted by specific antagonists.
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The BCR-ABL oncogenetic pathway
The ABL protein physiologically shuttles between the nucleus and the cytoplasm, however, when fused to BCR, the oncoprotein loses this property and it is mainly retained within the cytoplasm where it interacts with the majority of proteins involved in the oncogenic pathway. ABL tyrosine kinase activity is constitutively activated by the juxtaposition of BCR so favouring dimerization or tetramerization and the subsequent autophosphorylation. This increases the number of the phosphotyrosine residues on BCR-ABL and, as a consequence, the binding sites for the SH2 domains of other proteins. [6] [7] The abnormal interactions between the BCR-ABL oncoprotein and other cytoplasmic molecules leads to the disruption of key cellular processes. Some examples could be represented by the perturbation of the Ras-MAP kinase leading to increased proliferation, of the JAK-STAT pathway leading to impaired transcriptional activity and of the PI3K/Akt pathway resulting in increased apoptosis. 8 The aminoterminal BCR-encoded sequences of BCR-ABL contain a tyrosinephosphorylated site that binds the SH2 domain of the adaptor protein Grb2. 6 It is now evident that the phosphorylation of BCR Tyr177 is essential for BCR-ABL mediated leukemogenesis 9 and its mutation largely abolishes GRB2 binding and diminishes BCR-ABL induced Ras activation. 7 This latter results from interaction of BCR-ABL with other cytoplasmic proteins, which function as adaptor molecules, thus creating multiprotein signalling complexes. The BCR-ABL Grb2 complex recruits Sos, (Son of Sevenless), which is constitutively associated with the Grb2 SH3 domain. 10 In turn, the BCR-ABL-Grb2-Sos complex stimulates conversion of the inactive GDP-bound form of
Ras to its active GTP-bound state 11 and the activation of the scaffold adapter GRB2-associated binding protein 2 (GAB2). 12 As a consequence, GRB2/GAB2/SOS complex causes constitutive activation of RAS downstream pathway so activating MEK1/2 and MAPK proteins causing, as a final result, an abnormal cell proliferation. In addition this complex activates the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. 13 (figure 1) which promotes survival by
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Author Manuscript Published OnlineFirst on December 8, 2011; DOI: 10.1158/1078-0432.CCR- suppressing the activity of forkhead O (FOXO) transcription factor, enhance cell proliferation by inducing p27 proteosomal degradation and by mTOR activation.
In addition BCR-ABL, through PI3K/AKT/FOXO4 and finally through upregulation of mTOR potently blocks an important cellular process such as autophagy. BCR-ABL may activate PI3K by more than one pathway, since also Crk and Crkl have been shown to connect BCR-ABL with PI3K. 14, 15 Once activated, PI3K activates Akt kinase which represents a key downstream effector by exerting many cellular effects through the phosphorylation of downstream substrates including Bad, caspase 9, Mdm2 and Ask1 that regulate the apoptotic machinery, 16 therefore resulting into prolonged survival and expansion of the abnormal clone.
Key transcription factors are involved in BCR-ABL signalling. Among them a key role is played by STAT1 and STAT5 (signal transducer and activation of transcription) which are constantly active in BCR-ABL positive cell lines and in primary cells from CML patients contributing in the induction of cytokine independence.
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In normal cells, nuclear translocation of STATs occurs exclusively after cytokine binding to receptors and is mediated by activation of the receptor-associated JAK kinases. By contrast in CML STATs seem to be activated in a JAK independent manner, through a direct association of STATs SH2 domains with phosphorylated tyrosines on BCR-ABL. 18 Activation of STAT5 is, at least partially, responsible for protection from programmed cell death through the upregulation of the antiapoptotic molecule BCL-xL together with the inactivation of the proapoptotic molecule BAD by AKT. 8 Another postulated nuclear 'target' of the transforming activity of the BCR-ABL protein is represented by the protooncogene MYC, which is expressed at a high level in CML cells. MYC activation, however, seems to be independent from RAS pathway but it seems to be directly upregualted by ABL SH2 region. 19 There are several lines of evidence showing that Myc is often overexpressed in blast crisis compared with chronic phase, so linking MYC to progression. 19 In
Research. 19 All reported activated signalling pathways converge into a unique terminal point: loss of control of proliferation and expansion of the leukemic clone. Any effort in the understanding of the precise definition of the relative contribution of each signal transduction pathway to the leukemic process is an important area of research because the combination of a tyrosine kinase inhibitor together with a downstream inhibitor, may represent a further clinically successful strategy .
Despite the seemingly endless expansion of the list of pathways activated by BCR-ABL and the increasing complexity that is being revealed in these pathways, all of the transforming functions of BCR-ABL seem to be dependent on its tyrosine kinase activity. 20 This precondition has an incredible intrinsic clinical potential in view of a more and more sophisticated targeted therapy.
Clinical-Translational Advances
Kinase inhibitors
Imatinib, a small molecule tyrosine kinase inhibitor (TKI), was the first drug to be developed that was able to directly target BCR-ABL tyrosine kinase activity and to be tested in CML. 21 In a short time it has become the standard frontline therapy for all CML patients in early chronic phase (CP)
based on the response rates and the good tolerability demonstrated. 22 Despite the exciting results obtained with imatinib, after 8 years of follow-up the cumulative complete cytogenetic response (CCyR) rate for first-line imatinib treated patients was 83%, the event-free survival (EFS) rate was 81%, and the estimated overall survival (OS) rate 85%.
However, it should be considered that if the CCyR is not achieved after 12 months of imatinib therapy, the probability of progression or loss of response raise to 38%. Indeed, after 8 years of follow-up, it was assessed that early cytogenetic response is predictive of long-term outcome: the cytogenetic response is therefore considered a prognostic indicators of lack of events, whereas nonoptimal responders had poorer prognosis. 23 In addition, the degree of response is critical. The IRIS In phase II trials of patients with CP CML, dasatinib and nilotinib were associated with 2-year CCyR rates in imatinib-resistant patients of 45% and 41%. 24 Following the impressive results in patients with imatinib failure, dasatinib and nilotinib have been assessed in phase II studies in patients with newly diagnosed CML. The rate of CCyR at 12 months was 80% and the rate of major molecular response was 44% thus showing a superiority compared to imatinib standard treatment with a favorable toxic profile. 25 The results of these trials seem to indicate a superior efficacy of the more potent second-generation TKIs with respect to imatinib, particularly in terms of higher rates of CCyR and MMR, that, more importantly, also seem to lead to a decreased number of progressions The first is to target what is commonly defined as the Achilles heel which is represented by the emergence of BCR-ABL mutant clones, including T315I which are completely insensitive to the second generation TKIs. 26 Although very rare, this small fraction of patients developing these insensitive clones loose the response and progress during treatment.
An additional step forward compared to the present therapeutic possibilities is represented by the complete eradication of the leukemic stem cells which appear to be resistant to the TK inhibitors so representing a reservoir of the leukemic pool which could eventually favor the reappearance of the disease when TK inhibitors are stopped. 27 Although very rare, resistant patients at least in the majority of the cases, present mutated clones, particularly aggressive and resistant to the available drugs. 28 Resistance to the BCR-ABL inhibitors may arise from different mechanisms, including BCR-ABL amino acid mutations, gene amplification and mechanisms independent from BCR-ABL. 29 The T315I mutation at the gatekeeper residue is frequent in advanced phases of the disease and is one of the main cause of resistance, disrupting important contact points between the inhibitors and the enzyme. The complete eradication of the resistant clones could be, at least theoretically faced by making use of two different approaches: for patients developing mutations still sensitive to TKI a more potent inhibition of the TK activity seems to overcome the resistance. This can be obtained by switching to second generation TKs 24 or by increasing imatinib dose. 30 For patients with mutants insensitive to the available drugs a different and more complex approach is required. This is
Research. 31 Phase I study demonstrated the tolerability of the drug in all phases of CML as weel as in ALL.
A novel TK inhibitor is preclinical phase of development is represented by Deciphera. 32 It belongs to a class of TK inhibitors with the novel mechanism of action since it blocks the switch pocket rather than the ATP pocket. This compound has been demonstrate to inhibit, at least in vitro, all the mutant variants of BCR-ABL.
Molecular targets downstream of BCR-ABL
The alternative approach could be represented by targeting molecules downstream of BCR-ABL. It is a serine/threonine kinase made of two complexes, mTORC1 controlling transit from G1 phase to S phase of the cell cycle and mTORC2 which phosphorylates Akt leading to its full activation. 33 Rapamycin (sirolimis, Wyeth-Ayerst Laboratories) has emerged as a potent inhibitor of mTORC signalling. 34 . Several rapamycin analogs, CCI-779 34 RAD-001 35 and WYE-132 36 with improved pharmaceutical properties but similar biological effects to rapamycin, are currently undergoing clinical trials. Rapamycin and "rapalogs" are not able to inhibit mRNA translation and protein synthesis in different models of diseases. 37 The direct inhibition of protein synthesis represents a new emerging field of therapy. Therefore small molecules have been developed to target the mTOR kinase domain (Torin1, PP242, and PP30), in order to inhibit both mTORC1 and mTORC2 signaling pathways.
Research. activity by occupying the catalytic ATP binding site. 41 Many of these compounds resulted effective in inhibiting T315I mutants.
Stem cell pathways
An emerging concept in cancer biology is that a rare population of cancer stem cells exists among the heterogeneous cell mass that constitutes a tumor. 42 This concept applies also to CML. Normal and leukemic hematopoietic stem cell functions are defined by a common set of critical stemness genes that regulate self renewal. 43 Hematopoietic stem cells (HSCs) and leukemic stem cells (LSCs)
share common features: self renewal, the capacity to differentiate, resistance to apoptosis and limitless proliferative potential. 43 Despite these similarities, several stemness factors, such as Notch, BMI-1, Wnt show differential activation in HSC versus LSC. These differences could therefore be exploited therapeutically. 44 It is important to consider that stemness in leukemia is linked to self-renewal. It is extremely likely that LSC undergo self renewal and they are capable of recapitulating leukemia therefore the maintenance of the LSC pool represents a critical factor for the success of any therapeutic intervention. Therefore targeting stemness factors could be the key factor for a successful therapy catenin. In the absence of Wnt signaling β-catenin is retain in the cytoplasm through a direct interaction with Axin, APC and GSK3. The phosphorylation of β-catenin by GSK3 induced its rapid proteasome mediated degradation. 49 Following Wnt binding to a receptor complex composed of members of the Frizzled family the Axin/APC/GSK3 is inhibited leading to a block in β-catenin phosphorylation by GSK3. Hypophosphorylated β-catenin accumulates in the cytoplasm and is translocated to the nucleous where it regulates target gene expression. 49 Deregulation of the Wnt signaling pathway is a hallmark of several types of leukemias. 50 Different molecular mechanisms
Research. called stromal-derived factor 1, SDF1) and are located between vessels and bone. 52 Targeted deletion of CXCR4 (the ligand for CXCL12) led to a severe reduction in HSC numbers and increased chemosensitivity. 52 The interactions between CXCR4 and SDF1 are important in the localization and retention of HSC and progenitor cells within the niche and they play a critical role in colonization of the bone marrow by HSCs during early development as demonstrated by the evidence that SDF1 deficient embryos have severely reduced HSC numbers and function. 53 The interaction between CXCR4 and CXCL12 appears to be critical for leukemic cell maintenance.
The leukemic cells seem to have the unique capacity to directly modulate the niche at the expense of normal hematopoietic stem and progenitor cells 54 by down-regulating CXCL12 levels in the areas of leukemia infiltration. Stem cell factor, secreted by the leukemic cells, represents a further niche regulator leading to abnormal engraftment of normal HSC in the tumor-infiltrated microenvironment. There are emerging evidences that the complex interactions between LSCs and their niche may be targeted to selectively deplete the repopulating ability of LSCs and to favor the normal HSC counterparts. In order to obtain a selective eradication of LSCs the niche targeted therapy requires a high degree of selectivity towards the aberrant interaction between the leukemic clone and the microenvironment. 55 These could include self renewal pathways such as Notch or
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